Inthera Bioscience AG

Inthera is tackling “undruggable” targets with innovative chemistry for the design of small molecule inhibitors of intracellular protein-protein interactions. The most advanced of these first-in-class therapeutics, an oral modulator of dysregulated transcription, is currently entering the preclinical stage.